

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VI LLC
Petitioner,

v.

CELGENE CORPORATION
Patent Owner

Case IPR2015-01103
Patent 6,315,720

PATENT OWNER RESPONSE
PURSUANT TO 35 U.S.C. § 313 AND 37 C.F.R. § 42.107

TABLE OF CONTENTS

I. INTRODUCTION 1

II. BACKGROUND 3

 A. The history of thalidomide and the '501 patent 3

 B. By the filing date of the '720 patent, the methods claimed in the '501 patent had successfully prevented the predicted second thalidomide tragedy 4

 C. Celgene conceived of Enhanced S.T.E.P.S.[®] based on confidential, nonpublic information..... 5

III. CFAD HAS FAILED TO CARRY ITS BURDEN OF PROVING, BY A PREPONDERANCE OF THE EVIDENCE, THAT THE CLAIMED METHODS WOULD HAVE BEEN OBVIOUS 9

 A. CFAD's use of the wrong POSA dooms its obviousness analysis 11

 B. CFAD has failed to prove that there was a known need or problem to be solved at the time of the '720 patent's invention..... 16

 C. The asserted references do not disclose, teach, or suggest every element of the claimed inventions..... 20

 1. Claim Construction 20

 2. Scope and Content of the Prior Art..... 24

 (a) Mitchell..... 24

 (b) Dishman 27

 (c) Cunningham..... 29

 (d) Mundt..... 31

 (e) Mann, Vanchieri, Shinn, Linnarsson, Grönroos, Soyka, Hamera, Kosten, and Menill 33

3.	Differences between the claimed inventions and the prior art	34
(a)	Independent Claims 1 and 28	34
i.	Dishman would not have disclosed, taught, or suggested the claimed prescription approval code.....	35
ii.	The '720 patent could not have disclosed, taught, or suggested the claimed prescription approval code.....	37
iii.	Cunningham would not have disclosed, taught, or suggested the claimed prescription approval code.....	38
(b)	Dependent Claims 2-27 and 29-32	41
i.	Claims 5 and 6.....	41
ii.	Claim 10	48
iii.	Claim 17	49
D.	CFAD has failed to prove that a POSA would have been motivated to combine the asserted references.....	51
1.	A POSA would not have been motivated to combine Cunningham, Dishman, and Powell.....	52
2.	A POSA would not have been motivated to combine Mundt with Mitchell	58
3.	Applying Cunningham's approval code was beyond the level of ordinary skill in the art.....	59
IV.	CONCLUSION.....	60

I. INTRODUCTION

United States Patent No. 6,315,720 (the “’720 patent”) describes and claims improved methods for delivering potentially dangerous drugs, such as teratogenic drugs (in particular, thalidomide), to a patient while avoiding the occurrence of side effects (such as thalidomide-related birth defects). Ex. 1001 at Claims. The inventions were conceived as part of Celgene Corporation’s (“Celgene”) efforts to improve its existing System for Thalidomide Education and Prescription Safety, or S.T.E.P.S.[®], which had been used to control patient access to Celgene’s Thalomid[®] (thalidomide) drug product since it was approved by the U.S. Food and Drug Administration (“FDA”) in July 1998. The original 1998 S.T.E.P.S.[®] program is an embodiment of U.S. Patent No. 6,045,501 (the “’501 patent,” at issue in IPR2015-01092). Celgene’s improved program—Enhanced S.T.E.P.S.[®]—is an embodiment of the improved methods claimed in the ’720 patent.

Coalition for Affordable Drugs VI (“CFAD”) filed a petition for *inter partes* review (“Petition” or “Pet.”) seeking cancelation of claims 1-32 of the ’720 patent. The Board instituted trial on the only ground raised in the Petition—CFAD’s assertion that claims 1-32 would have been obvious over Mitchell, Dishman, Cunningham, Mundt, Mann, Vanchieri, Shinn, Linnarsson, Grönroos, Soyka, Hamera, Kosten, and Menill. Paper 22 at 25. CFAD’s Petition lacks merit for several reasons.

First, CFAD conducted its obviousness analysis through the eyes of the wrong person of ordinary skill in the art (“POSA”). Because obviousness must be judged from the POSA’s viewpoint, and because CFAD’s POSA is improper, CFAD’s arguments are deficient and fail as a matter of law.

Second, CFAD has failed to identify any known need or problem in the art at the time that the ’720 patent was filed in October 2000. Without such an identification, there is no reason to arrive at the claimed inventions and the claims cannot have been obvious.

Third, CFAD has failed to prove that the asserted references would have rendered the claimed inventions obvious because the references fail to disclose, teach, or suggest each and every element of the claimed inventions.

Fourth, CFAD has failed to prove that a POSA would have been motivated to combine the asserted references. As already noted, there was no problem to be solved at the time of the ’720 patent’s invention and, therefore, no motivation to combine the asserted references for that reason alone. Further, even if there had been a problem to be solved, CFAD’s expert admitted that he chose to combine at least Cunningham with the other asserted references because the ’720 patent claims recite a “prescription approval code.” In other words, Dr. Fudin admitted that he used the ’720 patent as a roadmap to arrive at the claimed methods. This hindsight-driven analysis is impermissible and requires denial of the Petition.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.